NCT03756766View on ClinicalTrials.gov

Understanding RSV: Severe Disease and the Long Term Consequences

Active, not recruitingOBSERVATIONAL
Enrollment

315

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
DIAGNOSTIC_TEST

RSV point of care testing

Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.

Trial Locations (2)

Unknown

Oxford University Hospitals NHS Trust, Oxford

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Oxford

All Listed Sponsors
collaborator

Innovative Medicines Initiative

OTHER

collaborator

Respiratory syncytial virus consortium in Europe

UNKNOWN

lead

University of Oxford

OTHER

NCT03756766 - Understanding RSV: Severe Disease and the Long Term Consequences | Biotech Hunter | Biotech Hunter